Yumanity Therapeutics Past Earnings Performance
Past criteria checks 0/6
Yumanity Therapeutics's earnings have been declining at an average annual rate of -14.5%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 43.6% per year.
Key information
-14.5%
Earnings growth rate
42.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 43.6% |
| Return on equity | -584.4% |
| Net Margin | -660.7% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Yumanity Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 5 | -32 | 20 | 0 |
| 30 Jun 22 | 5 | -39 | 20 | -1 |
| 31 Mar 22 | 6 | -44 | 19 | 0 |
| 31 Dec 21 | 8 | -40 | 20 | 0 |
| 30 Sep 21 | 11 | -66 | 19 | 0 |
| 30 Jun 21 | 13 | -62 | 18 | 1 |
| 31 Mar 21 | 10 | -52 | 16 | 0 |
| 31 Dec 20 | 7 | -51 | 12 | 0 |
| 30 Sep 20 | 3 | -23 | 10 | 0 |
| 30 Jun 20 | 0 | -25 | 9 | 0 |
| 31 Mar 20 | 0 | -32 | 8 | 0 |
| 31 Dec 19 | 0 | -31 | 7 | 0 |
Quality Earnings: YMTX is currently unprofitable.
Growing Profit Margin: YMTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: YMTX is unprofitable, and losses have increased over the past 5 years at a rate of 14.5% per year.
Accelerating Growth: Unable to compare YMTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: YMTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Return on Equity
High ROE: YMTX has a negative Return on Equity (-584.37%), as it is currently unprofitable.